PSP94 EXPRESSION AFTER ANDROGEN DEPRIVATION THERAPY: A COMPARATIVE STUDY WITH PROSTATE SPECIFIC ANTIGEN IN BENIGN PROSTATE AND PROSTATE CANCER
- 1 November 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (5) , 1819-1824
- https://doi.org/10.1016/s0022-5347(05)67113-3
Abstract
To examine the clinical use of PSP94 (prostate secretory protein of 94 amino acids) as an androgen independent marker, we conducted a comparative study of prostate samples including benign tissue and cancers which did and did not have androgen deprivation. Among 163 radical prostatectomy cases 75 had androgen deprivation before operation, while surgery was performed in the remainder without prior hormone treatment. Considering the pathological up grading following hormone therapy, contiguous sections from radical prostatectomy samples were stained for PSP94 and prostate specific antigen (PSA) by immunohistochemistry, and equivalent tumor foci were evaluated by assessing the intensity and extent of the staining. In untreated benign prostate tissue PSP94 and PSA staining was positive and identical in all sections in the no pretreatment group. However, PSP94 expression in the androgen deprivation group was significantly higher than PSA in intensity (p = 0.0005) and extent (p = 0.034). In untreated cancer cases PSP94 intensity and extent demonstrated strong inverse association with Gleason grade (p <0.0001). In contrast, PSA expression was high in every grade, resulting in no statistical association with tumor grade. In the androgen deprivation group PSA staining was decreased in every grade compared to the no pretreatment group. On the other hand, PSP94 expression was decreased in grade 3 tumor foci but increased in grades 4 and 5 tumor foci compared with samples of the corresponding grade in the no pretreatment group (p = 0.0034). PSP94 expression in benign prostate persists under androgen deprivation compared to PSA. PSP94 synthesis in high grade tumor appears to be activated in the absence of androgen stimulation, indicating the possible alternative pathways in the regulation of PSP94.Keywords
This publication has 26 references indexed in Scilit:
- cDNA, Genomic Cloning, and Gene Expression Analysis of Mouse PSP94 (Prostate Secretory Protein of 94 Amino Acids)DNA and Cell Biology, 1999
- Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castrationEndocrinology, 1995
- Detection of prostatic‐inhibin‐like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell lineThe Prostate, 1994
- A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell linesCancer Letters, 1993
- Beta‐microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinomaThe Prostate, 1993
- Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinomaThe Prostate, 1993
- Prognostic significance of antigenic heterogeneity, gleason grade, and ploidy of lymph node metastases in patients with prostate cancerThe Prostate, 1992
- Pathologic changes associated with androgen deprivation therapy for prostate cancerCancer, 1991
- Further studies on the synthesis and secretion of inhibin‐like material by rat ventral prostate explants in vitroThe Prostate, 1990
- Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancerThe Prostate, 1987